DCGO Quote, Financials, Valuation and Earnings

Astrana Health, Inc. has a net margin of -41.88% compared to DocGo, Inc.'s net margin of 0.11%. DocGo, Inc.'s return on equity of -20.69% beat Astrana Health, Inc.'s return on equity of 1.85%.

DocGo, Inc. has a consensus price target of $2.75, signalling upside risk potential of 176.27%. On the other hand Astrana Health, Inc. has an analysts' consensus of $40.2500 which suggests that it could grow by 88.53%. Given that DocGo, Inc. has higher upside potential than Astrana Health, Inc., analysts believe DocGo, Inc. is more attractive than Astrana Health, Inc..

DocGo, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.862, suggesting its less volatile than the S&P 500 by 13.753%.

DocGo, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocGo, Inc. pays -- of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend.

DocGo, Inc. quarterly revenues are $70.8M, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. DocGo, Inc.'s net income of -$29.7M is lower than Astrana Health, Inc.'s net income of $1.1M. Notably, DocGo, Inc.'s price-to-earnings ratio is 8.24x while Astrana Health, Inc.'s PE ratio is 112.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocGo, Inc. is 0.27x versus 0.36x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International, Inc. has a net margin of -41.88% compared to DocGo, Inc.'s net margin of 9.58%. DocGo, Inc.'s return on equity of -20.69% beat Cryo-Cell International, Inc.'s return on equity of --.

DocGo, Inc. has a consensus price target of $2.75, signalling upside risk potential of 176.27%. On the other hand Cryo-Cell International, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 96.59%. Given that DocGo, Inc. has higher upside potential than Cryo-Cell International, Inc., analysts believe DocGo, Inc. is more attractive than Cryo-Cell International, Inc..

DocGo, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cryo-Cell International, Inc. has a beta of 0.669, suggesting its less volatile than the S&P 500 by 33.089%.

DocGo, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International, Inc. offers a yield of 15.03% to investors and pays a quarterly dividend of $0.15 per share. DocGo, Inc. pays -- of its earnings as a dividend. Cryo-Cell International, Inc. pays out 510.2% of its earnings as a dividend.

DocGo, Inc. quarterly revenues are $70.8M, which are larger than Cryo-Cell International, Inc. quarterly revenues of $7.8M. DocGo, Inc.'s net income of -$29.7M is lower than Cryo-Cell International, Inc.'s net income of $749.4K. Notably, DocGo, Inc.'s price-to-earnings ratio is 8.24x while Cryo-Cell International, Inc.'s PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocGo, Inc. is 0.27x versus 1.11x for Cryo-Cell International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners, Inc. has a net margin of -41.88% compared to DocGo, Inc.'s net margin of -20.12%. DocGo, Inc.'s return on equity of -20.69% beat P3 Health Partners, Inc.'s return on equity of -223.63%.

DocGo, Inc. has a consensus price target of $2.75, signalling upside risk potential of 176.27%. On the other hand P3 Health Partners, Inc. has an analysts' consensus of $10.25 which suggests that it could grow by 102.97%. Given that DocGo, Inc. has higher upside potential than P3 Health Partners, Inc., analysts believe DocGo, Inc. is more attractive than P3 Health Partners, Inc..

DocGo, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison P3 Health Partners, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

DocGo, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocGo, Inc. pays -- of its earnings as a dividend. P3 Health Partners, Inc. pays out -- of its earnings as a dividend.

DocGo, Inc. quarterly revenues are $70.8M, which are smaller than P3 Health Partners, Inc. quarterly revenues of $345.3M. DocGo, Inc.'s net income of -$29.7M is higher than P3 Health Partners, Inc.'s net income of -$69.5M. Notably, DocGo, Inc.'s price-to-earnings ratio is 8.24x while P3 Health Partners, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocGo, Inc. is 0.27x versus 0.01x for P3 Health Partners, Inc.. Usually stocks with elevated PS ratios are considered overvalued.